Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.180 +5.9% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% NSU 0.170 +9.7% WM 0.085 +0.0% YGT 0.180 +5.9%

Healthcare

Page 32
  1. Apr 17, 2026 · 16:30 · MRVL

    Marvel Biosciences Closes Financing to Fuel Phase I Transition Amidst Patent Wins

    Marvel Biosciences Announces Closing of Convertible Debenture Offering

    01
  2. Apr 17, 2026 · 13:50 · EYE

    FDA Approval Fails to Halt Post-IPO Decline as Liquidity Concerns Mount

    Canadian Securities Exchange Reports March 2026 Performance Figures

    02
  3. Apr 17, 2026 · 13:50 · APPT

    UberDoc Health Technologies Corp.

    Canadian Securities Exchange Reports March 2026 Performance Figures

    03
  4. Apr 17, 2026 · 07:19 · VVTM

    Compliance Failure Overshadows Commercial Progress as Audit Deadline Missed

    VVT Med Announces Application for Management Cease Trade Order

    04
  5. Apr 16, 2026 · 18:04 · WOLF

    Strategic Pivot to Human Health Validates Growth Model Despite Leverage

    GREY WOLF ANIMAL HEALTH REPORTS FOURTH QUARTER AND YEAR END 2025 FINANCIAL RESULTS

    05
  6. Apr 16, 2026 · 16:57 · KNE

    Clinical Validation Continues as Commercial Restart Struggles to Generate Revenue

    Kane presents revyve data at wound care conference

    06
  7. Apr 16, 2026 · 16:30 · CRRX

    Regulatory Stability Confirmed as CareRx Enters Profitability Phase

    CareRx Welcomes Stability in Long-Term Care Pharmacy Funding in Ontario

    07
  8. Apr 16, 2026 · 11:00 · VPT

    TSXV Venture Exchange Listed Cardiac Imaging Platform

    The Infrastructure Play Hiding in Plain Sight Across Cardiac Care

    08
  9. Apr 16, 2026 · 09:15 · NRX

    NurExone Extends Runway Amid Rising Burn Rate as IND Prep Continues

    NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update

    09
  10. Apr 16, 2026 · 08:01 · PHRM

    PharmaTher Peptide Strategy Faces Regulatory Hurdles Amidst 89% Stock Decline

    PharmaTher Supports Proposed U.S. Peptide Reclassification, Reinforcing the Strategic Value of Its Microneedle Patch Platforms for Peptide Delivery

    10
  11. Apr 16, 2026 · 07:30 · BPC

    Regulatory Clarity Focus

    The Precision Peptide Company Applauds FDA Action Advancing Regulatory Clarity for Peptide Therapies

    11
  12. Apr 16, 2026 · 07:25 · KNE

    Clinical Validation Supports Commercial Restart, But Revenue Collapse and Dilution Risks Remain

    Kane Biotech Presents revyve(TM) Clinical Data at Symposium on Advanced Wound Care (SAWC) Spring Conference

    12
  13. Apr 16, 2026 · 07:00 · BLCO

    Bausch + Lomb ESG Push Overshadows Flat Margins as Debt Refinancing Looms

    Bausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling Program

    13
  14. Apr 16, 2026 · 07:00 · MRVL

    Marvel Biosciences Advances MB-204 Formulation Ahead of Phase I, But Data Integrity Concerns Linger

    Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders

    14
← Newer Older →